A prospective study of serum adiponectin and regression of metabolic syndrome: The ARIRANG study

Jang Young Kim, Dhananjay Yadav, Songvogue Ahn, Sangbaek Koh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Increased serum adiponectin levels may play a protective role in metabolic syndrome. However, few prospective studies have examined the effect of serum adiponectin in the improvement of metabolic components in subjects with metabolic syndrome. We investigated the association of serum adiponectin levels with the regression of metabolic syndrome in a population-based longitudinal study. A total of 1308 adults (575 men and 733 women) with metabolic syndrome at baseline were examined and followed. Baseline serum adiponectin concentrations were measured by radioimmunoassay. During an average of 2.6 years of follow-up, metabolic syndrome had disappeared in 184 men (29.8%) and 235 women (32.1%). In multivariable adjusted models, the odds ratio (95% confidence interval) for regression of metabolic syndrome comparing the highest to the lowest quartiles of adiponectin levels was 0.93 (0.56-1.53) in men and 2.48 (1.54-4.01) in women. Increased serum adiponectin is a predictor for the regression of metabolic syndrome in women. Adiponectin may have potential therapeutic applications in metabolic disease.

Original languageEnglish
Pages (from-to)201-205
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume466
Issue number2
DOIs
Publication statusPublished - 2015 Oct 16

Fingerprint

Adiponectin
Prospective Studies
Serum
Metabolic Diseases
Radioimmunoassay
Longitudinal Studies
Odds Ratio
Confidence Intervals
Population

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

@article{546591bf6e9e4033a922515ac0ac706d,
title = "A prospective study of serum adiponectin and regression of metabolic syndrome: The ARIRANG study",
abstract = "Increased serum adiponectin levels may play a protective role in metabolic syndrome. However, few prospective studies have examined the effect of serum adiponectin in the improvement of metabolic components in subjects with metabolic syndrome. We investigated the association of serum adiponectin levels with the regression of metabolic syndrome in a population-based longitudinal study. A total of 1308 adults (575 men and 733 women) with metabolic syndrome at baseline were examined and followed. Baseline serum adiponectin concentrations were measured by radioimmunoassay. During an average of 2.6 years of follow-up, metabolic syndrome had disappeared in 184 men (29.8{\%}) and 235 women (32.1{\%}). In multivariable adjusted models, the odds ratio (95{\%} confidence interval) for regression of metabolic syndrome comparing the highest to the lowest quartiles of adiponectin levels was 0.93 (0.56-1.53) in men and 2.48 (1.54-4.01) in women. Increased serum adiponectin is a predictor for the regression of metabolic syndrome in women. Adiponectin may have potential therapeutic applications in metabolic disease.",
author = "Kim, {Jang Young} and Dhananjay Yadav and Songvogue Ahn and Sangbaek Koh",
year = "2015",
month = "10",
day = "16",
doi = "10.1016/j.bbrc.2015.09.007",
language = "English",
volume = "466",
pages = "201--205",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

A prospective study of serum adiponectin and regression of metabolic syndrome : The ARIRANG study. / Kim, Jang Young; Yadav, Dhananjay; Ahn, Songvogue; Koh, Sangbaek.

In: Biochemical and Biophysical Research Communications, Vol. 466, No. 2, 16.10.2015, p. 201-205.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A prospective study of serum adiponectin and regression of metabolic syndrome

T2 - The ARIRANG study

AU - Kim, Jang Young

AU - Yadav, Dhananjay

AU - Ahn, Songvogue

AU - Koh, Sangbaek

PY - 2015/10/16

Y1 - 2015/10/16

N2 - Increased serum adiponectin levels may play a protective role in metabolic syndrome. However, few prospective studies have examined the effect of serum adiponectin in the improvement of metabolic components in subjects with metabolic syndrome. We investigated the association of serum adiponectin levels with the regression of metabolic syndrome in a population-based longitudinal study. A total of 1308 adults (575 men and 733 women) with metabolic syndrome at baseline were examined and followed. Baseline serum adiponectin concentrations were measured by radioimmunoassay. During an average of 2.6 years of follow-up, metabolic syndrome had disappeared in 184 men (29.8%) and 235 women (32.1%). In multivariable adjusted models, the odds ratio (95% confidence interval) for regression of metabolic syndrome comparing the highest to the lowest quartiles of adiponectin levels was 0.93 (0.56-1.53) in men and 2.48 (1.54-4.01) in women. Increased serum adiponectin is a predictor for the regression of metabolic syndrome in women. Adiponectin may have potential therapeutic applications in metabolic disease.

AB - Increased serum adiponectin levels may play a protective role in metabolic syndrome. However, few prospective studies have examined the effect of serum adiponectin in the improvement of metabolic components in subjects with metabolic syndrome. We investigated the association of serum adiponectin levels with the regression of metabolic syndrome in a population-based longitudinal study. A total of 1308 adults (575 men and 733 women) with metabolic syndrome at baseline were examined and followed. Baseline serum adiponectin concentrations were measured by radioimmunoassay. During an average of 2.6 years of follow-up, metabolic syndrome had disappeared in 184 men (29.8%) and 235 women (32.1%). In multivariable adjusted models, the odds ratio (95% confidence interval) for regression of metabolic syndrome comparing the highest to the lowest quartiles of adiponectin levels was 0.93 (0.56-1.53) in men and 2.48 (1.54-4.01) in women. Increased serum adiponectin is a predictor for the regression of metabolic syndrome in women. Adiponectin may have potential therapeutic applications in metabolic disease.

UR - http://www.scopus.com/inward/record.url?scp=84942293556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942293556&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2015.09.007

DO - 10.1016/j.bbrc.2015.09.007

M3 - Article

C2 - 26361142

AN - SCOPUS:84942293556

VL - 466

SP - 201

EP - 205

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -